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  THE QUALITATIVE DETERMINATION OF 
OSELTAMIVIR PHOSPHATE IN TAMIFLU® 
CAPSULE BY CYCLIC VOLTAMMETRY 
A gold electrode was used in the voltammetric determination of oseltamivir phosphate 
standard in 0.05 M NaHCO3. Oseltamivir phosphate as a standard and as a com-
ponent of Tamiflu® capsule exhibited the identical cyclic voltammogram. The peaks 
originating from excipients in the capsule did not appear under the applied electro-
chemical conditions. An electrochemical method for the qualitative determination of 
oseltamivir phosphate in Tamiflu® capsules by cyclic voltammetry was developed. The 
presence of oseltamivir phosphate as standard and as a content of Tamiflu® capsule in 
electrolyte as well as their concentrations were simultaneously checked by HPLC. The 
lack of the current/concentration dependency was established. The non-pretreated 
glassy carbon electrode cannot be used for the determination of oseltamivir phosphate 
under identical experimental conditions presented for the gold electrode. 
 
 
It is known that antivirals are valuable supple-
mentation to vaccines for the control and prevention of 
influenza [1], and are likely to be active against a new 
pandemic variant [2]. Oseltamivir phosphate (Figure 1) 
is the best known orally active neuraminidase inhibitor 
antiviral drug [3,4] that slows the spread of influenza 
virus between cells in the body by stopping the virus 
from chemically cutting ties with its host-cell median 
time to symptom alleviation is reduced by 0.5–1 days 
[5]. The neuraminidase inhibitors are effective against 
both influenza A and B and are considered less toxic 
and less likely to promote development of drug-resistant 
influenza than adamantanes [6]. 
 
Figure 1. Structural formula of oseltamivir phosphate. 
Oseltamivir phosphate can be identified by thin- 
-layer chromatography, specific optical rotation, infra-
red spectrophotometry and tests characteristic for ortho-
phosphates [7]. Determination, by International Pharma-
copeia, can be done by high-performance liquid chro-
matography [7,8] or by titration with perchloric acid [7]. 
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Other methods include capillary electrophoresis [9], 
spectrofluorometry [10], micellar electrokinetic chroma-
tography [11], colorimetric [12] and liquid chromato-
graphic methods [12,13] as well as LC–MS–MS [14]. 
The voltammetric determination and electrochemical 
behavior of oseltamivir phosphate as well as its deter-
mination in Tamiflu® capsules have not been published.  
The aim of the present study was the qualitative 
voltammetric determination of oseltamivir phosphate as 
standard and in Tamiflu® capsules. Gold and glassy car-
bon electrodes were tested as working electrodes under 
identical experimental conditions using 0.05 M NaHCO3 
(pH 8.4) as a supporting electrolyte. During the voltam-
metric investigation of oseltamivir phosphate standard 
and oseltamivir phosphate in the Tamiflu® capsules, the 
presence of oseltamivir phosphate was confirmed by the 
simultaneous HPLC determination. 
EXPERIMENTAL 
Materials 
Oseltamivir phosphate has not been officially ap-
proved for use according to pharmacopeia and conse-
quently, it is not possible to order the reference EDQM 
standard. Oseltamivir phosphate (Roche), kindly pro-
vided by the Medicines and Medical Devices Agency of 
Serbia (Belgrade, Serbia) was used as a pure substance 
without further purification. A comparative experiment 
was performed with capsulated oseltamivir phosphate 
(30 mg) marketed by Roche as Tamiflu®, which, in ad-
dition to oseltamivir contained the following excipients: 
talk, povidon, sodium stearil fumarate, corn starch and 
sodium croscarmellose. We dissolved 25 mg of osel-
tamivir phosphate in 10 cm3 of 0.05 M NaHCO3 (stock 
solution) and added into electrolyte in equal aliquots 
starting from 1 cm3. 25 mg of Tamiflu® was dissolved in 
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solution containing 9 cm3 of 0.05 M NaHCO3 and 1 cm3 
CH3OH (stock solution) and added into electrolyte in 
equal aliquots starting from 1 cm3. CH3OH and NaHCO3 
were of analytical grade (Merck). The supporting elec-
trolyte, 0.05 M NaHCO3 was prepared with 18 MΩ de-
ionised water. 
Apparatus 
Standard equipment was used for the cyclic vol-
tammetry measurements using a three electrode electro-
chemical cell, as previously described in detail [15–17]. 
Polycrystalline gold (surface area 0.500 cm2) and glassy 
carbon Sigmadur GMBH Germany (surface area 0.29 
cm2) which served as the working electrodes were pre-
pared as earlier [15–17]. A gold wire was used as the 
counter electrode and a saturated calomel electrode as 
the reference electrode. All the potentials are given ver-
sus SCE. The electrolyte was deoxygenated by purging 
with nitrogen. 
The characteristics of the HPLC instrument are al-
ready described in detail [15–17] and the HPLC method 
performed during the simultaneous electrochemical ex-
periment for oseltamivir determination has been pub-
lished by Lindegardh et al. [14]. 
RESULTS AND DISCUSSION 
In our study of electrochemical behavior of oselta-
mivir phosphate and development of the appropriate 
method, a solution of oseltamivir phosphate standard 
was prepared as described in the Experimental part and 
used in the cyclic voltammetry measurements. In the 
first part of the work the gold electrode was used. The 
cyclic voltammogram of the clean gold electrode of 
oseltamivir phosphate (0.025 mg cm–3) is presented in 
Figure 2. Simultaneous HPLC analysis of the bulk of 
electrolyte confirmed that 0.025 mg cm–3 oseltamivir 
phosphate is presented in the electrolyte. Starting from 
–1.2 V one can observe an apparent reversible oxida-
tive/reductive reaction between –0.5 and –0.7 V. In the 
anodic direction, the anodic current increases from 0.4 
V and reaches the maximum starting from the area of 
the oxides formation. In the entire region of oxides 
formation at the gold electrode, the oxidative activity of 
oseltamivir phosphate is obvious. The lowering of the 
oxides reduction currents can also be noticed from the 
cyclic voltammogram. Starting from –0.8 V the exact 
same reactions were observed as it was obtained starting 
from –1.2 V, and as it is presented in Figure 3. The po-
tential was cycled continuously for two hours and the 
cyclic voltammogram was quite stable in both cases. Hold-
ing the potential for 10 min at the peak potentials and in 
the area of oxide formation did not affect the voltam-
mogram even in the first sweep. The cyclic voltammo-
gram of oseltamivir phosphate at the gold electrode in 
0.05 M NaHCO3 (Figures 2 and 3) is quite reproducible. 
With the addition of the next two aliquotes of stock so-
lution of oseltamivir phosphate containing 2.5 mg cm–3, 
the linearity of the current–concentration dependency 
was not observed, and even the voltammogram remain-
ed the same. With the simultaneous HPLC analysis of 
the bulk of electrolyte, the presence of the added con-
centrations was confirmed. 
 
Figure 2. Cyclic voltammogram of the clean gold electrode in 
0.05 M NaHCO3 (dash line) and in the presence of 0.025 
mg cm–3 oseltamivir phosphate (full line) in the area of the 
potential from –1.2 to 1.0 V, sweep rate 50 mV/s. 
 
Figure 3. Cyclic voltammogram of the clean gold electrode in 
0.05 M NaHCO3 (dash line) and in a presence of 0.025 
mg cm-3 oseltamivir phosphate (full line) in the area of the 
potential from –0.8 to 1.0 V, sweep rate 50 mV/s. 
Additionally, the glassy carbon electrode was tested 
as a working electrode in the same manner of the elec-
trode cleaning and under identical experimental condi-
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tions as it was presented for the gold electrode. Starting 
from –1.2 V as well as from –0.8 V in the presence of 
0.025 mg cm–3 oseltamivir phosphate the cyclic voltam-
mogram of glassy carbon electrode was the same as 
without it. The non-pretreated glassy carbon electrode 
cannot be used as the working electrode.  
In addition, the determination of oseltamivir phos-
phate in Tamiflu® capsules was performed at the gold 
electrode. The cyclic voltammograms of the gold elec-
trode in a presence of 0.025 mg cm–3 Tamiflu® were 
surprisingly the same as given for 0.025 mg cm–3 of 
oseltamivir phosphate standard (Figures 2 and 3). The 
cyclic voltammogram of Tamiflu® also remain stable 
during the cycling. With the addition of the next two 
aliquots of stock solution of Tamiflu® the voltammo-
gram remaines the same and with the simultaneous HPLC 
analysis of the bulk of electrolyte, the presence of the 
added concentrations was confirmed. 
The cyclic voltammograms of Tamiflu® are quite 
reproducible. According to identical cyclic voltammo-
grams of oseltamivir phosphate standard (Figures 2 and 
3) and Tamiflu® capsule content it is evident that oselta-
mivir phosphate can be qualitatively determined in cap-
sule Tamiflu® at gold electrode in 0.05 M NaHCO3. 
The excipients presented in Tamiflu capsules: talk, 
sodium stearil fumarate, corn starch and sodium cros-
carmelose are insoluble in water [18]. Besides oselta-
mivir phosphate, only povidon is soluble in water, but it 
is obvious that it is not electroactive under the condi-
tions presented in Figure 2. The excipients were separa-
tely tested in our previous investigations [15–17,19] 
concerning commercial pharmaceutical compounds. The 
present excipients did not affect the electroactivity of 
oseltamivir phosphate in Tamiflu® capsule. It is qualita-
tively determined as the component of the capsule Ta-
miflu® Roche in the same way as the pure standard. The 
qualitative determination of oseltamivir phosphate as 
standard and in Tamiflu® capsule in any case should not 
be compared with our previously published results con-
cerning qualitative determination of macrolide antibio-
tics [15–17] obtained under the same experimental con-
ditions. Azithromycin, clarithromycin and erythromycin 
are strongly dependent on the starting potential –1.2 V 
and with the starting potential –0.8 V, they are com-
pletely inactive on the gold electrode. The peak poten-
tials, peak height and peak reversibility are quite diffe-
rent for each antibiotic standard as well as for oselta-
mivir phosphate standard. Antibiotics in capsules and 
tablets in the presence of the excipients exhibit signifi-
cantly different electrochemical behavior and conse-
quently the different cyclic volltamograms comparing to 
their standards. Only oseltamivir phosphate exhibits the 
quite same cyclic voltammogram as a standard and as a 
content of Tamiflu® capsule. 
CONCLUSION 
In conclusion, it should be pointed out that a simp-
le and fast voltammetric method for the qualitative de-
termination of oseltamivir phosphate was developed and 
applied for the qualitative determination of oseltamivir 
phosphate in Tamiflu® capsules. Starting from –1.2 V as 
well as from –0.8 V, an apparent reversible oxideti-
ve/reductive reaction between –0.5 and –0.7 V occurs. 
In the anodic direction, the anodic current increases 
from 0.4 V and reaches a maximum starting from the 
area of the oxides formation. In the entire region of the 
oxides formation at the gold electrode this maximum 
oxidative currents of oseltamivir phosphate remain un-
changed. The lowering of the oxides reduction currents 
is also noticed. The identical cyclic voltammograms of 
oseltamivir phosphate standard and of Tamiflu® capsule 
content showed that oseltamivir phosphate is quailta-
tively determined in Tamiflu® capsule content at the 
gold electrode in 0.05 M NaHCO3. The glassy carbon 
electrode cannot be used as working electrode and did 
not exhibited any affinity to the oxidative/reductive re-
actions of oseltamivir phosphate starting from –1.2 V as 
well as from –0.8 V.  
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IZVOD 
KVALITATIVNO ODREĐIVANJE OSELTAMIVIR-FOSFATA U TAMIFLU® KAPSULAMA POMOĆU 
CIKLIČNE VOLTAMETRIJE 
Milka L. Avramov Ivić1, Slobodan D. Petrović2,3, Dušan Ž. Mijin2, Katica M. Drljević-Đurić4 
1IHTM – Centar za Elektrohemiju, Univerzitet u Beogradu, Beograd 
2Tehnološko-metalurški fakultet, Univerzitet u Beogradu, Beograd 
3Hemofarm Stada, Farmaceutsko hemijska industrija, Vršac 
4Agencija za lekove i medicinska sredstva Srbije, Beograd 
(Naučni rad) 
Aktuelna ispitivanja lekova zahtevaju razvoj brzih metoda za prepoz-
navanje standarda lekova u komercijalnim kapsulama i tabletama. U opse-
gu potencijala od –1,2 V kao i od –0,8 V do 1,0 V oseltamivir-fosfat kao 
standard i sastojak Tamiflu® kapsule podleže oksidativno-reduktivnoj re-
akciji između –0,5 i –0,7 V kao i anodnoj reakciji počevši od 0.4 V, sa 
platoom struja uočenih u celom opsegu potencijala formiranja oksida na
elektrodi od zlata. Oseltamivir-fosfat kao standard i kao komponenta Ta-
miflu® kapsule snižava struje redukcije oksida na zlatu. Držanje poten-
cijala na vrednostima pojave pikova ne utiče na promenu cikličnog volta-
mograma, tj. na navedene reakcije. Cikliziranje potencijala u toku više
časova ne dovodi do promene cikličnog voltamograma u oba opsega po-
tencijala. Ciklični voltamogram za koncentraciju oseltamivir-fosfata kao 
standarda i kao sastojka Tamiflu® kapsule od 0,025 mg cm–3 bio je iden-
tičan i po dodatku naredne dve koncentracije pa se na elektrodi od zlata ne
može ispitivati i koncentraciona zavisnost u 0,05 M NaHCO3. Koncen-
tracije leka u elektrolitu su potvrđene simultanom HPLC analizom prema
aktuelnoj farmakopeji. Ekscipijenti prisutni u Tamiflu® kapsuli nisu ni na 
koji način uticali na ponašanje oseltamivir-fosfata kao standarda, tj. ne-
aktivni su pod primenjenim eksperimentalnim uslovima. Elektroda od sta-
klastog ugljenika je takođe testirana u oba opsega potencijala i pod iden-
tičnim eksperimentalnim uslovima je potpuno neaktivna, za razliku od ele-
ktrode od zlata, u prisustvu oseltamivir-fosfata kao standarda i kao sastoj-
ka Tamiflu® kapsule. Elektroda od zlata se u navedenim opsezima poten-
cijala koristeći 0,05 M NaHCO3 kao elektrolit i pod navedenim elektrohe-
mijskim uslovima može efikasno koristiti za kvalitativno određivanje osel-
tamivir-fosfata u Tamiflu kapsuli. 
 Ključne reči: Oseltamivir-fosfat • Ta-
miflu® • Kapsula • Ciklična volta-
metrija • HPLC  
Key words: Oseltamivir phosphate •
Tamiflu® • Capsule • Cyclic voltam-
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